

**Media Contact**

Carol Berry, MBA
Chief Business Officer, SVP
Caprion
cberry@caprion.com
514.360.3600

**Caprion Poster Presentation at the 2015 American Association of
Pharmaceutical Scientists Annual Meeting*****Development of a Novel P700 Plasma Peptidomic Platform***

Montreal, Canada – October 27, 2015 - Caprion announced today it will have a poster presentation at the American Association of Pharmaceutical Scientist Annual Meeting being in Orlando, Florida, October 25-29. The poster presentation features a novel peptidomic platform for the identification of endogenous peptides in P700 plasma allows for the detection of low pM peptides including PYY. The platform is robust and sensitive with good precision and accuracy. The sensitivity and reproducibility of the peptidomic platform allowed the identification of several endogenous peptides that may be involved in insulin resistance and diabetes.

“Development of a Novel P700 Plasma Peptidomic Platform”

Poster #T3334: Tuesday Oct. 27th
Session Time: 01:30 pm - 05:00 pm
Location: Exhibit Hall WB1-WB2

Mark H. Watson¹, Michael Schirm¹, Rudolf Guilbaud¹, Karine Gilbert¹, Chunyan Li¹, Ying-Tzy S. Lin¹, Marija Mentinova¹, Lorella Di Donato¹, David G. McLaren² and Gregory J. Opitck².

¹Caprion Proteome Inc., Montreal Canada

²Merck & Company, Inc., Rahway, NJ, USA

About Caprion

Caprion is the leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its immune monitoring business unit, ImmuneCarta[®], offers proprietary multiparametric flow cytometry for functional analyses of innate and adaptive immune responses. Caprion’s proteomics business unit, ProteoCarta[™], offers proprietary gel-free, label-free mass spectrometry (MS) for comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers. Caprion also leverages ProteoCarta to develop its own in-vitro diagnostic products targeting cancer, metabolic

and infectious diseases. With research sites in Montreal, Canada and in Menlo Park, CA, Caprion has been providing large-scale proteomics and immune monitoring services to over 50 major pharmaceutical and biotech clients for more than 10 years. Caprion, a privately-held company, is majority owned by Chicago Growth Partners. For more information, please visit www.caprion.com.